* Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.
0.05% sodium azide
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Product Specific Information
This antibody is predicted to react with rat based on sequence homology.
Suggested positive control: Hela whole cell extract.
CYLD is a 956 aa, cytoplasmic, deubiquitinating enzyme belonging to the ubiquitin carboxy-terminal hydrolases (UCH) family of proteins with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains, a proline rich region, a SH3 binding domain and a sequence homology to catalytic domain of UCH. CYLD is identified as a tumor suppressor protein affecting the JNK signaling pathway. CYLD is a negative regulator of TRAF2 and NF-kappa-B signaling pathway and is also known to have receptor-dependent role in regulating the I-kappa-B kinase pathway. It also has a deubiquitinating activity that is directed towards non-Lys-48-linked polyubiquitin chains and TRAP1 is a novel substrate for deubiquitination. Mutated CYLD is known to be associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome.
CYLD Antibody (PA1-41097) in WB anti-CYLD_Polyclonal_Antibody_(PA1-41097)_WB.jpg
Western Blot with anti-CYLD Polyclonal Antibody (PA1-41097)